S'abonner

Aeroallergen sensitization correlates with PC20 and exhaled nitric oxide in subjects with mild-to-moderate asthma - 15/08/11

Doi : 10.1016/j.jaci.2007.12.1153 
Timothy J. Craig, DO a, , Tonya S. King, PhD b, Robert F. Lemanske, MD c, Michael E. Wechsler, MD d, Nikolina Icitovic, MS b, Ronald R. Zimmerman, BA b, Stephen Wasserman, MD e

National Heart, Lung, and Blood Institute’s Asthma Clinical Research Network

a Divisions of Pulmonary, Allergy, and Critical Care, Pennsylvania State University College of Medicine, Hershey, Pa 
b Division of Public Health Sciences, Department of Medicine, Pennsylvania State University College of Medicine, Hershey, Pa 
c Division of Allergy, Immunology, Department of Pediatrics, University of Wisconsin, Madison, Wis 
d Pulmonary Division, Department of Medicine, Brigham and Women’s Hospital, Boston, Mass 
e Division of Allergy, Immunology, Department of Medicine, University of California, San Diego, Calif 

Reprint requests: Timothy J. Craig, DO, Thoracic Medicine Professional Services, Pennsylvania State University College of Medicine, H041, Hershey, PA 17033-0853.

Abstract

Background

Aeroallergen sensitization in adult asthmatic patients from a wide geographic area has not been correlated with patients’ characteristics, markers of airways inflammation, and lung function.

Objective

We assessed data obtained from the Asthma Clinical Research Network trials to determine the relationship of aeroallergen sensitization to age, sex, ethnicity, and markers of inflammation and airways function.

Methods

Skin testing (14 epicutaneous) was performed on 1338 subjects with objectively diagnosed mild-to-moderate asthma from 11 Asthma Clinical Research Network studies. Skin testing used identical techniques and a quality assurance program to ensure uniformity across centers.

Results

Ninety-five percent of the subjects had at least 1 positive skin test response. Of these, 14% had positive reactions to 1 or 2 allergens and 81% had positive reactions to 3 or more allergens, and 2% of subjects reacted only to seasonal allergens, 26% only to perennial allergens, and 67% to both. Increasing IgE and exhaled nitric oxide values, decreasing PC20 values, and minority ethnicity significantly correlated with the number of positive skin test responses. Subjects with late-onset asthma were less likely to be sensitized; nonetheless, 89% of subjects older than 60 years had positive responses.

Conclusion

Ninety-five percent of patients with mild-to-moderate asthma might have an allergic component. Age does not significantly affect aeroallergen sensitization, but the pattern of allergic sensitization varies with ethnicity and geography. Measures used to characterize asthma, such as IgE, exhaled nitric oxide, and PC20 values, are correlated with aeroallergen sensitization.

Le texte complet de cet article est disponible en PDF.

Key words : Asthma, allergy, skin testing, aeroallergens, exhaled nitric oxide, IgE, methacholine challenge

Abbreviations used : ACRN, eNO, FVC


Plan


 Supported by grants U10-HL51831, U10-HL51845, U10-HL51823, U10-HL51843, U10-HL56443, U10-HL51834, U10-HL51810, U10-HL74227, U10-HL74231, U10-HL74204, U10-HL74212, U10-HL74073, U10-HL74206, U10-HL74208, U10-HL74225, and U10-HL74218.
 Disclosure of potential conflict of interest: T. J. Craig is on the advisory board for Aventis; has consulting arrangements with Genentech/Novarits, Glaxo, Schering-Plough, and AstraZeneca; and has received research support from Schering-Plough, Merck, Glaxo, ACAAI, Methaparm, Dyax, Lev, PDL, Centacore, Sanofi-Aventis, and Altana. R. F. Lemanske has consulting arrangements with Novartis, Merck, GlaxoSmithKline, Aventis, and AstraZeneca; has received research support from the National Heart, Lung, and Blood Institute; and is on the speakers’ bureau for Merck and GlaxoSmithKline. M. E. Weshsler has consulting arrangements with Genentech, Novartis, Merck, Aerocrine, Graceway, and Schering-Plough; has received research support from GlaxoSmithKline; an is on the speakers’ bureau for Genentech, Novartis, Merck, and GlaxoSmithKline. S. Wasserman has consulting arrangements with AstraZeneca, Genentech, Novartis, Tanex, Icos, Vistakon, Tanabe, and Amylin; has received research support from GlaxoSmithKline, and Schering-Plough; is on the speakers’ bureau for AstraZeneca; has served as an expert witness in medical malpractice cases about anaphylaxis, asthma, and drug allergies; and has served as an expert witness on the health effects of mold exposure. The rest of the authors have declared that they have no conflict of interest.


© 2008  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 121 - N° 3

P. 671-677 - mars 2008 Retour au numéro
Article précédent Article précédent
  • Reducing asthma health disparities in poor Puerto Rican children: The effectiveness of a culturally tailored family intervention
  • Glorisa Canino, Doryliz Vila, Sharon-Lise T. Normand, Edna Acosta-Pérez, Rafael Ramírez, Pedro García, Cynthia Rand
| Article suivant Article suivant
  • Exposure to multiple indoor allergens in US homes and its relationship to asthma
  • Päivi M. Salo, Samuel J. Arbes, Patrick W. Crockett, Peter S. Thorne, Richard D. Cohn, Darryl C. Zeldin

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2025 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.